

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Studying effectiveness of Short Term oral Magnesium supplement Prophylaxis In Menstrually Related Migraine (MRM) in women in reproductive ages : A Randomized Controlled Trial

#### Protocol summary

##### Study aim

Evaluate effect of short term oral magnesium prophylaxis on prevention, frequency, intensity, prolongation, amount of analgesic drugs and resulting palliation In Menstrually Related Migraine (MRM) headache attacks.

##### Design

In this blinded, randomized, concealed clinical trial with a parallel group design patients examine for 3 continuous months in magnesium users and placebo users subgroups.

##### Settings and conduct

Each qualified patient fill out questionnaire about her MRM headache attacks features in 1 month without any magnesium or placebo usage initially, then a third person divides participants into magnesium and placebo groups randomly (random allocation rule) and also he is the only person who has access to patient's personal information, then he gives out tablets according to each person's group and after passing 3 months he collect questionnaires and records data and reports them anonymously to researcher and analyzer.

##### Participants/Inclusion and exclusion criteria

Women of reproductive age who have regular menses and affected by Menstrually Migraine, meet the last International Classification of Headache Disorders's (ICHD) criteria for MRM and doesn't fill the exclusion criteria that was named.

##### Intervention groups

Half of the qualified patients use 375 milligrams oral magnesium (magnesium oxide tablets) and the other half also use placebo tablets which are exactly the same size, smell and color, for 3 continuous Menstrual cycles from fifteenth day of each cycle to the third day of next one.

##### Main outcome variables

group (magnesium and placebo), age, menstrual cycle

length, headache frequency, intensity, prolongation, amount of analgesic drugs and resulting palliation, side effects

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190415043284N1**

Registration date: **2019-08-15, 1398/05/24**

Registration timing: **retrospective**

Last update: **2019-08-15, 1398/05/24**

Update count: **0**

##### Registration date

2019-08-15, 1398/05/24

##### Registrant information

##### Name

pegah Yabande jahrom

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 61 3373 8255

##### Email address

yabande.p@ajums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-01-21, 1397/11/01

##### Expected recruitment end date

2019-03-16, 1397/12/25

##### Actual recruitment start date

2019-01-21, 1397/11/01

**Actual recruitment end date**

2019-04-19, 1398/01/30

**Trial completion date**

2019-07-21, 1398/04/30

**Scientific title**

Studying effectiveness of Short Term oral Magnesium supplement Prophylaxis In Menstrually Related Migraine (MRM) in women in reproductive ages : A Randomized Controlled Trial

**Public title**

Short Term Magnesium Prevention In Menstrually Related Migraine (MRM)

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

patients affected by menstrually related migraine according to 3rd edition of The International Classification of Headache Disorders regular mense

**Exclusion criteria:**

chronic diarrhea renal failure nephrolithiasis myasthenia gravis patients anti hypertensive drug usage particularly calcium channel blocker users diabetic patients who has insulin resistance state pregnancy or planned pregnancy; ; menstrual migraine [14] breast feeding women non migraine headache psychiatric illness according to DSM5 criteria chronic systemic illness dependence or abuse of drugs intake of antidepressants, neuroleptics, minor or major tranquillizers, drugs used for the treatment of affective disorders (e.g. lithium, carbamazepine), antiepileptics bradrychardia anti coagulant and antiplatelet usage pure menstrually migraine

**Age**

From **20 years** old to **50 years** old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Participant
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **60**

Actual sample size reached: **42**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Participants assign to comparison groups (allocation sequence) with random allocation rule (a form of restricted randomisation procedures- after sample taking finished, we put magnesium and placebo papers, half and half number in a sortition container and bring them out randomly to make an allocation sequence.) and this allocation conceals by central randomization.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Participants are unaware of who is receiving the real

treatment and by means of a third party who collected data and bring them anonymous to assessor and and analyser blinding done.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Ahvaz Jundishapur University of Medical Sciences

**Street address**

No. 3, Mahsa building, Alley 13, Khadem Sadeq Ave., Amir Kabir Blv., shiraz

**City**

Ahvaz

**Province**

Khuzestan

**Postal code**

۷۱۷۸۷۴۳۵۹

**Approval date**

2018-05-05, 1397/02/15

**Ethics committee reference number**

IR.AJUMS.REC.1397.083

**Health conditions studied****1****Description of health condition studied**

Menstrually Related Migraine (MRM)

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

headache attacks of menstrually related migraine

**Timepoint**

4 questionnaires are filled: the first one at the sampling time and 3 others during 3 continuous menstrual cycles which the participant take pills.

**Method of measurement**

questionnaire

**Secondary outcomes**

**1**

**Description**

headache frequency, intensity, prolongation, amount of analgesic drugs and resulting palliation

**Timepoint**

4 questionnaires are filled: the first one at the sampling time and 3 others during 3 continuous menstrual cycles which the participant take pills.

**Method of measurement**

Each questionnaire contains a calendar with blanks to record: the exact date of menstruation starting date, headache days, headache intensity ( 1 to 10 scale), each headache attack prolongation (hours), number of analgesic pills to pain relief and resulting palliation (describes with excellent, good, intermediate and poor response)

**Intervention groups**

**1**

**Description**

Intervention group: each patient during 3 continuous menstrual cycles, taking one and half (375 milligrams) of 250 miligrames magnesium oxide pills from Jalinous Pharmaceutical company daily and records headaches from 2 days before menstruation up to third day of mens. Control group: each patient during 3 continuous menstrual cycles, taking one and half of placebo pills daily and records headaches from 2 days before menstruation up to third day of mens.

**Category**

Prevention

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Golestan hospital

**Full name of responsible person**

Ehsan Mohammadiani Nejad

**Street address**

Neurology ward, Golestan hospital, Farvardin Aven., Golestan Blv..

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

33118-61357

**Phone**

+98 61 3374 3001

**Email**

p.yabande@gmail.com

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Mohammad Badavi

**Street address**

Ahvaz jundishapur university of medical sciences, Golestan Blv.

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

15794-61357

**Phone**

+98 61 3373 8383

**Email**

p.yabande@gmail.com

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Ahvaz University of Medical Sciences

**Proportion provided by this source**

30

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Ehsan Mohammadiani Nejad

**Position**

Assistant professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Neurology

**Street address**

Neurology ward, Golestan hospital, Farvardin Aven., Golestan Blv..

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

33118-61357

**Phone**

+98 61 3374 3001

**Email**  
p.yabande@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Ahvaz University of Medical Sciences  
**Full name of responsible person**  
Ehsan Mohammadiani Nejad  
**Position**  
Assistant professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Neurology  
**Street address**  
Neurology ward, Golestan hospital, Farvardin Aven.,  
Golestan Blv..  
**City**  
Ahvaz  
**Province**  
Khouzestan  
**Postal code**  
33118-61357  
**Phone**  
+98 61 3374 3001  
**Email**  
p.yabande@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Ahvaz University of Medical Sciences  
**Full name of responsible person**  
Ehsan Mohammadiani Nejad  
**Position**  
assistant professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Neurology  
**Street address**  
Neurology ward, Golestan hospital, Farvardin Aven.,  
Golestan Blv..  
**City**  
Ahvaz  
**Province**

Khouzestan

**Postal code**  
33118-61357

**Phone**  
+98 61 3374 3001

**Email**  
p.yabande@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Not applicable

### Data Dictionary

Not applicable

### Title and more details about the data/document

Data about magnesium prophylaxis effects on menstrually related migraine headaches and its Side effects will share.

### When the data will become available and for how long

at least 6 months after the date that results have been published.

### To whom data/document is available

researchers who work for universities

### Under which criteria data/document could be used

To investigate weak points of this study to obtain and start a new and more useful work

### From where data/document is obtainable

Dr Ehsan Mohammadiani Nejad, neurology ward, Ahvaz Jundishapur university of medical sciences

### What processes are involved for a request to access data/document

Deliver a request containing exact description of reasons for this request and make a list of the exact data which is needed, to the neurology group. this request will be checked as soon as possible and will be answered.

### Comments